Meeting
2021 ASCO Annual Meeting
Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.
Authors
Jeffrey S. Weber
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY
Jeffrey S. Weber , Helen Gogas , Xiaowu Sun , Christine Yip , Fiona Taylor , Julia Braverman , Maurice Lobo , Pratik K. Thakkar , Andriy Moshyk , James Larkin , Paolo Antonio Ascierto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02388906
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9574)
DOI
10.1200/JCO.2021.39.15_suppl.9574
Abstract #
9574
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
First Author: Maria Constantinou
Poster
2024 ASCO Annual Meeting
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
First Author: Nikhil I. Khushalani
Poster
2024 ASCO Annual Meeting
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
First Author: Minke W. Lucas
Poster
2023 ASCO Annual Meeting
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
First Author: Peter Kar Han Lau